About Products and Technologies
Yes. The therapiAI Agent Platform is purpose-built for pharmaceutical companies, CDMOs, and CMC workflows.
Through AI-driven collaboration, it streamlines R&D processes, shortens development cycles, reduces trial-and-error experiments, accelerates GMP document generation, and enhances business decision-making.
It supports departments across R&D, PD, QA, and BD, enabling end-to-end intelligent transformation.
The platform provides AI-powered image analysis, prediction, and inference to identify high-potential cell lines, significantly reducing experimental time and manpower cost while improving R&D efficiency and production competitiveness.
Optimax integrates image-recognition models with machine learning to predict high-productivity cell lines at early stages, shortening the screening process and reducing manual culturing workload.
Yes. therapiAI supports standard API integration with LIMS, QMS, ERP, and other enterprise systems.
Most projects can begin fine-tuning with as few as 500 data entries, without retraining the entire AI engine, and customized onboarding plans are provided.
Yes. Projects can start with small datasets (around 500 entries).
If data is limited, therapiAI specialists can provide tailored implementation plans to ensure successful deployment.
.
Optimax visualizes key variables and parameter interactions, helping researchers analyze results faster, enhance cross-team communication, and improve overall research efficiency.
Yes. The platform uses a “non-retained, non-centralized” data architecture.
All computation takes place within the client’s private cloud, ensuring data security and regulatory compliance.
Yes. The therapiAI Agent Platform incorporates continuous-learning mechanisms, enabling models to improve prediction accuracy over time as new data is added.
Cooperation and Implementation Process
Our main clients are medium to large pharmaceutical companies and CDMOs with stable production lines and regulatory requirements.
Flexible collaboration plans are available for companies of different scales.
.
therapiAI adopts a subscription-based model, supporting both long-term enterprise deployment and flexible onboarding for new clients.
For details, please contact our team.
.
Clients report shorter R&D cycles, reduced trial-and-error costs, faster document review, improved BD performance, and higher delivery efficiency.
Yes. therapiAI provides API and on-premise integration services, connecting with systems such as LIMS, ERP, and GMP document management platforms to ensure secure and efficient workflows.
Differentiation and Competitive Advantages
AI delivers core value in CDMO operations—optimizing processes, improving scheduling, predicting quality outcomes, automating documentation, reducing costs, and driving intelligent manufacturing transformation.
Unlike companies focusing on drug discovery or clinical analytics (e.g., BenchSci, Recursion), therapiAI focuses on CDMO process management and compliance documentation, offering AI Agents that directly integrate with production environments and deliver tangible, measurable value.
Because CDMOs operate in the most complex, data-intensive, and regulation-heavy environments.
therapiAI aims to build AI Agents that truly understand CDMO workflows and can be trusted and deployed quickly—helping define future standards for intelligent pharmaceutical manufacturing.
.
For its strong focus on compliance, trustworthiness, and measurable outcomes.
therapiAI simultaneously delivers value at both the production-line and regulatory levels,
supported by multiple proven success cases.
contact@therapiai.bio
therapiAI is an AI company headquartered in Taipei, Taiwan, specializing in AI Agents for the pharmaceutical CDMO sector.
Its solutions enhance efficiency and compliance across R&D and manufacturing workflows.
Michael Han.
therapiAI was founded by Michael Han, Alicja Lee, and Polly Lin.
The team includes AI engineers, biomedical scientists, regulatory specialists, and industry advisors.
The company’s predecessor, Akousist, was founded in 2018.
It rebranded to therapiAI in 2024 to focus on accelerating CMC/CDMO workflows with AI.
“To make pharmaceutical manufacturing smarter, more efficient, and more trustworthy.”
Our mission is to rebuild CMC workflows through AI and establish the foundation for intelligent manufacturing.
therapiAI is headquartered in Taipei, Taiwan, serving pharmaceutical and CDMO clients across the Asia-Pacific region.